STOCK TITAN

Integrated BioPharma (INBP) Stock Price, News & Analysis

INBP OTC
Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
47 178 sessions, November 14, 2025 to November 16, 2026
Largest daily move
-18.6% close of May 20, 2026
1-year change
-34% closing prices, November 14, 2025 to November 16, 2026
1-month change
-2.8% closing prices, October 15, 2026 to November 16, 2026

Company Description

Integrated BioPharma, Inc. (INBP) is a manufacturing company in the pharmaceutical preparation manufacturing industry that focuses primarily on vitamins, nutritional supplements and herbal products. According to multiple company press releases, Integrated BioPharma is engaged in the manufacturing, distributing, marketing and sales of these products, positioning it within the broader nutraceutical and supplement segment of the manufacturing sector.

The company’s common stock trades under the symbol INBP, and press releases describe it as operating through activities that include contract manufacturing. In several quarterly and annual results announcements, Integrated BioPharma refers to a Contract Manufacturing Segment and notes that revenue from its two largest customers in this segment represents a substantial portion of total revenue. These disclosures indicate that contract manufacturing for third parties is a central part of its operations.

Business focus and activities

In the "About Integrated BioPharma, Inc." sections of its financial results releases, the company consistently states that it is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. Integrated BioPharma Inc produces and supplies nutraceutical products rather than focusing on proprietary pharmaceutical drugs.

The company’s results commentary frequently references its core business and efforts to expand its customer base. Management statements in earnings releases discuss revenue concentration in the Contract Manufacturing Segment and note that revenue from the two largest customers has represented a high percentage of total revenue in recent fiscal years and interim periods. These comments underscore both the importance of contract manufacturing and the company’s stated goal of diversifying its customer base.

Customer concentration and segments

Across multiple reporting periods, Integrated BioPharma discloses that its two largest customers in the Contract Manufacturing Segment account for a significant majority of total revenue. For example, company press releases for periods ended June 30, December 31, March 31 and September 30 in various years provide percentages showing that these two customers together contributed a large share of revenue. In one fiscal year discussion, the company also notes that its Contract Manufacturing Segment contributed the vast majority of total revenue, with additional contribution from another nutraceutical business segment described as warehousing and distribution.

Management commentary in these releases links the company’s strategy to both supporting its existing core businesses and pursuing new prospects in contract manufacturing and warehousing and distribution, with the stated objective of diversifying the customer base over time.

Regulatory and corporate governance context

Integrated BioPharma is incorporated in Delaware, as indicated in its SEC filings, including Form 8-K and its definitive proxy statement on Schedule 14A. The company’s proxy materials describe a Board of Directors divided into classes serving staggered three-year terms and outline typical annual meeting matters such as election of directors, advisory votes on executive compensation and its frequency, and ratification of the independent auditor.

The company files current reports on Form 8-K to announce financial results for quarters and fiscal years, furnishing earnings press releases as exhibits. It also files a definitive proxy statement (DEF 14A) for its annual meeting of stockholders, which provides information on proposals to be voted on, voting procedures and record date details. These filings show that Integrated BioPharma follows standard U.S. public company governance and disclosure practices.

Stockholder and meeting information

According to the company’s proxy statement and related Form 8-K, Integrated BioPharma holds an annual meeting of stockholders where holders of its common stock vote on director elections, advisory compensation matters and auditor ratification. The proxy materials specify that each share of common stock is entitled to one vote on matters presented at the meeting and describe how stockholders of record and beneficial owners can vote by mail, telephone, internet or in person.

Form 8-K disclosures regarding the annual meeting provide final voting results for each proposal, including director elections, advisory votes on executive compensation and the frequency of such votes, and ratification of the independent auditor for a specified fiscal year. These filings confirm that the company maintains an active stockholder voting process and reports outcomes through the SEC’s EDGAR system.

Financial reporting and results communication

Integrated BioPharma regularly issues press releases detailing its financial results for quarters and fiscal years, and these releases are referenced in corresponding Form 8-K filings under Item 2.02 (Results of Operations and Financial Condition). The releases include summaries of revenue, cost of sales, gross profit, selling and administrative expenses, operating income or loss, other income or expense, income tax expense or benefit, and net income or loss, along with basic and diluted net income (loss) per share and weighted average shares outstanding.

In the narrative portions of these releases, the company’s Co-Chief Executive Officers comment on revenue trends, operating performance and revenue concentration in the Contract Manufacturing Segment. They also refer to focusing on core businesses, expanding the customer base and, in some periods, growth in warehousing and distribution activities within the nutraceutical business.

Trading and registration status

Several press releases identify Integrated BioPharma’s stock as trading on the OTCQX market under the symbol INBP. In recent Form 8-K filings, the section listing securities registered under Section 12(b) of the Exchange Act states that the company has no securities registered on a national securities exchange, with "None" shown for both the title of each class and the exchange. This indicates that while the company’s common stock trades, it is not listed on a national securities exchange under Section 12(b) as of the dates of those filings.

The company’s SEC filings also reference its Commission File Number and employer identification number, confirming its status as a registrant under the Securities Exchange Act of 1934. The filings include standard checkboxes regarding solicitation material and pre-commencement communications, which are not selected in the provided documents.

Use of SEC and investor materials

In its proxy statement, Integrated BioPharma notes that its proxy statement and annual report on Form 10-K for a given fiscal year are available through a specified proxy materials website. The proxy explains how stockholders can access these materials and describes the matters to be considered at the annual meeting. The company’s financial press releases also direct interested parties to its investor relations site for further information.

For investors researching INBP stock, these disclosures together present a picture of a nutraceutical-focused manufacturer that emphasizes contract manufacturing relationships, vitamins, nutritional supplements and herbal products, and that communicates results and governance matters through regular press releases, SEC filings and annual meeting materials.

Stock Performance

$0.1750
-
-
Last updated: November 16, 2026 at 16:00
-34%
Performance 1 year

Integrated BioPharma (INBP) closed at $0.1750 on November 16, 2026. Over the past 12 months, the price has lost 34.0%.

See what a $1,000 investment in INBP would be worth today

Average down calculator for INBP

INBP Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

Integrated BioPharma generated $43.9M in revenue in FY2026, retaining a 1.8% gross margin, operating income reached -$2.7M (-6.2% operating margin), and net income was -$2.8M, reflecting a -6.5% net profit margin. Diluted earnings per share stood at -$0.09. The company generated $1.2M in operating cash flow. The current ratio was 3.00, measuring current assets divided by current liabilities.

$43.9M
Revenue (FY2026)
-$2.8M
Net Income (FY2026)
$1.2M
Operating Cash Flow

Upcoming Events

No upcoming events scheduled for INBP.

Short Interest History

Last 12 Months

Short interest in Integrated BioPharma (INBP) currently stands at 509 shares, representing 0.0% of the float. Since November 2025, short interest has decreased by 83.0%.

Days to Cover History

Last 12 Months

Days to cover for Integrated BioPharma (INBP) currently stands at 1.0 days. The ratio is the reported short interest divided by the average daily trading volume. Across the settlements charted above, it has ranged from 1.0 to 5.7 days.

INBP Company Profile & Sector Positioning

Integrated BioPharma (INBP) operates in the Packaged Foods industry within the broader Consumer Defensive sector and is listed on the OTC.

Investors comparing INBP often look at related companies in the same sector, including BAB Inc (BABB), Cyanotech Corp (CYAN), Limitless X Holdings Inc (LIMX), Buron NutraScience Corp (BRCNF), and Glucose Health Inc (GLUC). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate INBP's relative position within its industry.

Frequently Asked Questions

The current stock price of Integrated BioPharma (INBP) is $0.1750 as of November 16, 2026.

The market cap of Integrated BioPharma (INBP) is approximately $5.4M. Learn more about what market capitalization means .

The FY2026 revenue of Integrated BioPharma (INBP) is $43.9M, from its most recent completed fiscal year.

The FY2026 net income of Integrated BioPharma (INBP) is -$2.8M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Integrated BioPharma (INBP) is -$0.09 for FY2026, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Integrated BioPharma (INBP) is $1.2M for FY2026, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of Integrated BioPharma (INBP) is -6.5% for FY2026, its most recent completed fiscal year. Learn about profit margins.

The operating profit margin of Integrated BioPharma (INBP) is -6.2% for FY2026, its most recent completed fiscal year. Learn about operating margins.

The gross profit margin of Integrated BioPharma (INBP) is 1.8% for FY2026, its most recent completed fiscal year. Learn about gross margins.

The current ratio of Integrated BioPharma (INBP), current assets divided by current liabilities, was 3.00 at the end of FY2026, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of Integrated BioPharma (INBP) is $800K for FY2026, its most recent completed fiscal year.

The operating income of Integrated BioPharma (INBP) is -$2.7M for FY2026, its most recent completed fiscal year. Learn about operating income.

According to its financial press releases, Integrated BioPharma, Inc. is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The company operates within the pharmaceutical preparation manufacturing industry and focuses on nutraceutical products.

Company press releases describe a Contract Manufacturing Segment and state that revenue from the two largest customers in this segment represents a high percentage of total revenue in various reporting periods. This indicates that contract manufacturing services for vitamins, nutritional supplements and herbal products are a major source of revenue.

Integrated BioPharma is described as operating in the pharmaceutical preparation manufacturing industry within the broader manufacturing sector. Its activities center on nutraceutical products such as vitamins, nutritional supplements and herbal products.

SEC filings, including Form 8-K and the definitive proxy statement, identify Integrated BioPharma, Inc. as a Delaware corporation. The company’s name and state of incorporation appear in the heading sections of these filings.

In its earnings press releases, the company refers to itself as Integrated BioPharma, Inc. (OTCQX:INBP). Recent Form 8-K filings show that the company has no securities registered under Section 12(b) of the Exchange Act, indicating that its common stock trades on the OTCQX market rather than a national securities exchange.

In multiple financial results releases, Integrated BioPharma refers to a Contract Manufacturing Segment and notes that revenue from its two largest customers in this segment accounts for a substantial portion of total revenue. This segment relates to contract manufacturing activities for vitamins, nutritional supplements and herbal products.

Management commentary in several press releases states that revenue from the company’s two largest customers in the Contract Manufacturing Segment has represented a high percentage of total revenue in recent quarters and fiscal years. The company also notes efforts to expand its customer base and reduce reliance on these significant customers.

The company’s definitive proxy statement and related Form 8-K describe annual meeting proposals that include electing a Class III director for a three-year term, providing advisory votes on executive compensation and the frequency of such votes, and ratifying the appointment of the independent auditor for a specified fiscal year.

Integrated BioPharma issues press releases announcing its quarterly and annual financial results, and these are furnished as exhibits to Form 8-K filings under Item 2.02 (Results of Operations and Financial Condition). The releases provide summaries of revenue, operating income or loss, net income or loss and related metrics.

In a discussion of its fiscal year results, the company notes that its Contract Manufacturing Segment contributed the vast majority of total revenue and refers to growth in another nutraceutical business segment, described as warehousing and distribution. This indicates that warehousing and distribution activities also form part of its nutraceutical operations.